Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 389


The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.

Lin R, Xia S, Shan C, Chen D, Liu Y, Gao X, Wang M, Kang HB, Pan Y, Liu S, Chung YR, Abdel-Wahab O, Merghoub T, Rossi M, Kudchadkar RR, Lawson DH, Khuri FR, Lonial S, Chen J.

Mol Cell. 2018 Mar 15;69(6):923-937.e8. doi: 10.1016/j.molcel.2018.02.010.


The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer.

Jin L, Chun J, Pan C, Kumar A, Zhang G, Ha Y, Li D, Alesi GN, Kang Y, Zhou L, Yu WM, Magliocca KR, Khuri FR, Qu CK, Metallo C, Owonikoko TK, Kang S.

Mol Cell. 2018 Jan 4;69(1):87-99.e7. doi: 10.1016/j.molcel.2017.11.025. Epub 2017 Dec 14.


The OncoPPi Portal: an integrative resource to explore and prioritize protein-protein interactions for cancer target discovery.

Ivanov AA, Revennaugh B, Rusnak L, Gonzalez-Pecchi V, Mo X, Johns MA, Du Y, Cooper LAD, Moreno CS, Khuri FR, Fu H.

Bioinformatics. 2017 Nov 24. doi: 10.1093/bioinformatics/btx743. [Epub ahead of print]


California dreaming.

Khuri FR.

Cancer. 2017 Dec 1;123(23):4528-4529. doi: 10.1002/cncr.31070. Epub 2017 Oct 4. No abstract available.


Gene methylation biomarkers in sputum as a classifier for lung cancer risk.

Leng S, Wu G, Klinge DM, Thomas CL, Casas E, Picchi MA, Stidley CA, Lee SJ, Aisner S, Siegfried JM, Ramalingam S, Khuri FR, Karp DD, Belinsky SA.

Oncotarget. 2017 Jul 15;8(38):63978-63985. doi: 10.18632/oncotarget.19255. eCollection 2017 Sep 8.


Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.

Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, Khuri FR, Ahmed R, Ramalingam SS.

Cancer. 2018 Jan 15;124(2):271-277. doi: 10.1002/cncr.31043. Epub 2017 Sep 28.


Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status.

Zhang J, Nannapaneni S, Wang D, Liu F, Wang X, Jin R, Liu X, Rahman MA, Peng X, Qian G, Chen ZG, Wong KK, Khuri FR, Zhou W, Shin DM.

Oncotarget. 2017 Aug 1;8(35):59008-59022. doi: 10.18632/oncotarget.19779. eCollection 2017 Aug 29.


Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence.

Belinsky SA, Leng S, Wu G, Thomas CL, Picchi MA, Lee SJ, Aisner S, Ramalingam S, Khuri FR, Karp DD.

Cancer Prev Res (Phila). 2017 Nov;10(11):635-640. doi: 10.1158/1940-6207.CAPR-17-0177. Epub 2017 Sep 13.


HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Pillai RN, Behera M, Berry LD, Rossi MR, Kris MG, Johnson BE, Bunn PA, Ramalingam SS, Khuri FR.

Cancer. 2017 Nov 1;123(21):4099-4105. doi: 10.1002/cncr.30869. Epub 2017 Jul 25.


OncoPPi-informed discovery of mitogen-activated protein kinase kinase 3 as a novel binding partner of c-Myc.

Ivanov AA, Gonzalez-Pecchi V, Khuri LF, Niu Q, Wang Y, Xu Y, Bai Y, Mo X, Prochownik EV, Johns MA, Du Y, Khuri FR, Fu H.

Oncogene. 2017 Oct 19;36(42):5852-5860. doi: 10.1038/onc.2017.180. Epub 2017 Jun 19.


A better angel of our nature: Hanna Michel "Jean" Khoury, MD (April 24, 1967-May 22, 2017).

Khuri FR.

Cancer. 2017 Aug 15;123(16):2998-3002. doi: 10.1002/cncr.30847. Epub 2017 Jun 16. No abstract available.


HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers.

Zhao L, Fan J, Xia S, Pan Y, Liu S, Qian G, Qian Z, Kang HB, Arbiser JL, Pollack BP, Kudchadkar RR, Lawson DH, Rossi M, Abdel-Wahab O, Merghoub T, Khoury HJ, Khuri FR, Boise LH, Lonial S, Chen F, Chen J, Lin R.

J Biol Chem. 2017 Jun 16;292(24):10142-10152. doi: 10.1074/jbc.M117.788778. Epub 2017 May 3.


Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.

Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, Sica GL, Yu K, Koenig L, Patel NT, Behera M, Wu H, McCausland M, Chen Z, Zhang C, Khuri FR, Owonikoko TK, Ahmed R, Ramalingam SS.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998. doi: 10.1073/pnas.1705327114. Epub 2017 Apr 26.


Corrigendum: The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies.

Li Z, Ivanov AA, Su R, Gonzalez-Pecchi V, Qi Q, Liu S, Webber P, McMillan E, Rusnak L, Pham C, Chen X, Mo X, Revennaugh B, Zhou W, Marcus A, Harati S, Chen X, Johns MA, White MA, Moreno CS, Cooper LAD, Du Y, Khuri FR, Fu H.

Nat Commun. 2017 Apr 18;8:15350. doi: 10.1038/ncomms15350. No abstract available.


Modulation of Bax and mTOR for Cancer Therapeutics.

Li R, Ding C, Zhang J, Xie M, Park D, Ding Y, Chen G, Zhang G, Gilbert-Ross M, Zhou W, Marcus AI, Sun SY, Chen ZG, Sica GL, Ramalingam SS, Magis AT, Fu H, Khuri FR, Curran WJ, Owonikoko TK, Shin DM, Zhou J, Deng X.

Cancer Res. 2017 Jun 1;77(11):3001-3012. doi: 10.1158/0008-5472.CAN-16-2356. Epub 2017 Apr 5.


Targeting adhesion signaling in KRAS, LKB1 mutant lung adenocarcinoma.

Gilbert-Ross M, Konen J, Koo J, Shupe J, Robinson BS, Wiles WG 4th, Huang C, Martin WD, Behera M, Smith GH, Hill CE, Rossi MR, Sica GL, Rupji M, Chen Z, Kowalski J, Kasinski AL, Ramalingam SS, Fu H, Khuri FR, Zhou W, Marcus AI.

JCI Insight. 2017 Mar 9;2(5):e90487. doi: 10.1172/jci.insight.90487.


Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis.

Jin L, Chun J, Pan C, Alesi GN, Li D, Magliocca KR, Kang Y, Chen ZG, Shin DM, Khuri FR, Fan J, Kang S.

Oncogene. 2017 Jul 6;36(27):3797-3806. doi: 10.1038/onc.2017.6. Epub 2017 Feb 20.


The OncoPPi network of cancer-focused protein-protein interactions to inform biological insights and therapeutic strategies.

Li Z, Ivanov AA, Su R, Gonzalez-Pecchi V, Qi Q, Liu S, Webber P, McMillan E, Rusnak L, Pham C, Chen X, Mo X, Revennaugh B, Zhou W, Marcus A, Harati S, Chen X, Johns MA, White MA, Moreno C, Cooper LA, Du Y, Khuri FR, Fu H.

Nat Commun. 2017 Feb 16;8:14356. doi: 10.1038/ncomms14356.


MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development.

Harati S, Cooper LA, Moran JD, Giuste FO, Du Y, Ivanov AA, Johns MA, Khuri FR, Fu H, Moreno CS.

PLoS One. 2017 Jan 24;12(1):e0170339. doi: 10.1371/journal.pone.0170339. eCollection 2017.


Five more years! Not everything changes.

Khuri FR.

Cancer. 2017 Mar 1;123(5):724-727. doi: 10.1002/cncr.30552. Epub 2017 Jan 17. No abstract available.


Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.

Xia S, Lin R, Jin L, Zhao L, Kang HB, Pan Y, Liu S, Qian G, Qian Z, Konstantakou E, Zhang B, Dong JT, Chung YR, Abdel-Wahab O, Merghoub T, Zhou L, Kudchadkar RR, Lawson DH, Khoury HJ, Khuri FR, Boise LH, Lonial S, Lee BH, Pollack BP, Arbiser JL, Fan J, Lei QY, Chen J.

Cell Metab. 2017 Feb 7;25(2):358-373. doi: 10.1016/j.cmet.2016.12.010. Epub 2017 Jan 12.


AKT1, LKB1, and YAP1 Revealed as MYC Interactors with NanoLuc-Based Protein-Fragment Complementation Assay.

Mo X, Qi Q, Ivanov AA, Niu Q, Luo Y, Havel J, Goetze R, Bell S, Moreno CS, Cooper LA, Johns MA, Khuri FR, Du Y, Fu H.

Mol Pharmacol. 2017 Apr;91(4):339-347. doi: 10.1124/mol.116.107623. Epub 2017 Jan 13.


Association of Cytoplasmic CXCR4 With Loss of Epithelial Marker and Activation of ERK1/2 and AKT Signaling Pathways in Non-Small-Cell Lung Cancer.

Saba NF, Wang Y, Fu H, Koenig L, Khuri FR, Shin DM, Chen ZG.

Clin Lung Cancer. 2017 May;18(3):e203-e210. doi: 10.1016/j.cllc.2016.12.005. Epub 2016 Dec 22.


Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base.

Steuer CE, Behera M, Liu Y, Fu C, Gillespie TW, Saba NF, Shin DM, Pillai RN, Pakkala S, Owonikoko TK, Khuri FR, Ramalingam SS.

Clin Lung Cancer. 2017 May;18(3):286-292. doi: 10.1016/j.cllc.2016.11.016. Epub 2016 Dec 7.


The known unknown.

Khuri FR.

Cancer. 2017 Jan 1;123(1):17-19. doi: 10.1002/cncr.30487. No abstract available.


National Cancer Database Analysis of Proton Versus Photon Radiation Therapy in Non-Small Cell Lung Cancer.

Higgins KA, O'Connell K, Liu Y, Gillespie TW, McDonald MW, Pillai RN, Patel KR, Patel PR, Robinson CG, Simone CB 2nd, Owonikoko TK, Belani CP, Khuri FR, Curran WJ, Ramalingam SS, Behera M.

Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):128-137. doi: 10.1016/j.ijrobp.2016.10.001. Epub 2016 Oct 11.


Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.

Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, Pakkala S, Pillai RN, Owonikoko TK, Curran WJ, Belani CP, Khuri FR, Ramalingam SS.

JAMA Oncol. 2017 Aug 1;3(8):1120-1129. doi: 10.1001/jamaoncol.2016.4280. Review.


Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth.

Fan J, Lin R, Xia S, Chen D, Elf SE, Liu S, Pan Y, Xu H, Qian Z, Wang M, Shan C, Zhou L, Lei QY, Li Y, Mao H, Lee BH, Sudderth J, DeBerardinis RJ, Zhang G, Owonikoko T, Gaddh M, Arellano ML, Khoury HJ, Khuri FR, Kang S, Doetsch PW, Lonial S, Boggon TJ, Curran WJ, Chen J.

Mol Cell. 2016 Dec 1;64(5):859-874. doi: 10.1016/j.molcel.2016.10.014. Epub 2016 Nov 17.


Financial Burden of Cancer Drug Treatment in Lebanon.

Elias F, Khuri FR, Adib SM, Karam R, Harb H, Awar M, Zalloua P, Ammar W.

Asian Pac J Cancer Prev. 2016;17(7):3173-7.


HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.

Wang D, Qian G, Zhang H, Magliocca KR, Nannapaneni S, Amin AR, Rossi M, Patel M, El-Deiry M, Wadsworth JT, Chen Z, Khuri FR, Shin DM, Saba NF, Chen ZG.

Clin Cancer Res. 2017 Feb 1;23(3):677-686. doi: 10.1158/1078-0432.CCR-16-0558. Epub 2016 Jun 29.


Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin.

Elf S, Lin R, Xia S, Pan Y, Shan C, Wu S, Lonial S, Gaddh M, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Boggon TJ, Fan J, Chen J.

Oncogene. 2017 Jan 12;36(2):254-262. doi: 10.1038/onc.2016.196. Epub 2016 Jun 6.


Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.

Owonikoko TK, Zhang G, Kim HS, Stinson RM, Bechara R, Zhang C, Chen Z, Saba NF, Pakkala S, Pillai R, Deng X, Sun SY, Rossi MR, Sica GL, Ramalingam SS, Khuri FR.

J Transl Med. 2016 May 3;14(1):111. doi: 10.1186/s12967-016-0861-5.


Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma.

Behera M, Owonikoko TK, Gal AA, Steuer CE, Kim S, Pillai RN, Khuri FR, Ramalingam SS, Sica GL.

Clin Lung Cancer. 2016 Sep;17(5):e57-e64. doi: 10.1016/j.cllc.2016.03.009. Epub 2016 Mar 30. Review.


RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis.

Alesi GN, Jin L, Li D, Magliocca KR, Kang Y, Chen ZG, Shin DM, Khuri FR, Kang S.

Oncogene. 2016 Oct 13;35(41):5412-5421. doi: 10.1038/onc.2016.79. Epub 2016 Apr 4.


Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.

Fisher KE, Zhang L, Wang J, Smith GH, Newman S, Schneider TM, Pillai RN, Kudchadkar RR, Owonikoko TK, Ramalingam SS, Lawson DH, Delman KA, El-Rayes BF, Wilson MM, Sullivan HC, Morrison AS, Balci S, Adsay NV, Gal AA, Sica GL, Saxe DF, Mann KP, Hill CE, Khuri FR, Rossi MR.

J Mol Diagn. 2016 Mar;18(2):299-315. doi: 10.1016/j.jmoldx.2015.11.006. Epub 2016 Jan 20.


Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.

Steuer CE, Behera M, Berry L, Kim S, Rossi M, Sica G, Owonikoko TK, Johnson BE, Kris MG, Bunn PA, Khuri FR, Garon EB, Ramalingam SS.

Cancer. 2016 Mar 1;122(5):766-72. doi: 10.1002/cncr.29812. Epub 2015 Dec 22.


Enabling systematic interrogation of protein-protein interactions in live cells with a versatile ultra-high-throughput biosensor platform.

Mo XL, Luo Y, Ivanov AA, Su R, Havel JJ, Li Z, Khuri FR, Du Y, Fu H.

J Mol Cell Biol. 2016 Jun;8(3):271-81. doi: 10.1093/jmcb/mjv064. Epub 2015 Nov 16.


Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers.

Anisuzzaman AS, Haque A, Rahman MA, Wang D, Fuchs JR, Hurwitz S, Liu Y, Sica G, Khuri FR, Chen ZG, Shin DM, Amin AR.

Cancer Prev Res (Phila). 2016 Jan;9(1):63-73. doi: 10.1158/1940-6207.CAPR-15-0240. Epub 2015 Oct 28.


Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8/TRAF2-mediated signaling.

Oh YT, Yue P, Wang D, Tong JS, Chen ZG, Khuri FR, Sun SY.

Oncotarget. 2015 Dec 1;6(38):41324-38. doi: 10.18632/oncotarget.5847.


LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions.

Liu F, Jin R, Liu X, Huang H, Wilkinson SC, Zhong D, Khuri FR, Fu H, Marcus A, He Y, Zhou W.

Oncotarget. 2016 Jan 19;7(3):2519-31. doi: 10.18632/oncotarget.6224.


Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells.

Webber PJ, Park C, Qui M, Ramalingam SS, Khuri FR, Fu H, Du Y.

Oncoscience. 2015 Sep 15;2(9):765-776. eCollection 2015.


6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.

Lin R, Elf S, Shan C, Kang HB, Ji Q, Zhou L, Hitosugi T, Zhang L, Zhang S, Seo JH, Xie J, Tucker M, Gu TL, Sudderth J, Jiang L, Mitsche M, DeBerardinis RJ, Wu S, Li Y, Mao H, Chen PR, Wang D, Chen GZ, Hurwitz SJ, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Lei Q, Brat DJ, Ye K, Boggon TJ, He C, Kang S, Fan J, Chen J.

Nat Cell Biol. 2015 Nov;17(11):1484-96. doi: 10.1038/ncb3255. Epub 2015 Oct 19. Review.


Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.

McKibbin T, Cheng LL, Kim S, Steuer CE, Owonikoko TK, Khuri FR, Shin DM, Saba NF.

Support Care Cancer. 2016 Apr;24(4):1789-93. doi: 10.1007/s00520-015-2978-0. Epub 2015 Oct 7.


Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.

Behera M, Ragin C, Kim S, Pillai RN, Chen Z, Steuer CE, Saba NF, Belani CP, Khuri FR, Ramalingam SS, Owonikoko TK.

Cancer. 2016 Jan 1;122(1):50-60. doi: 10.1002/cncr.29674. Epub 2015 Oct 6.


Perspective on the National Comprehensive Cancer Network's Clinical Practice Guidelines for Smoking Cessation.

Ostroff JS, Goffin JR, Khuri FR, Warren GW.

J Oncol Pract. 2016 Jan;12(1):55-8. doi: 10.1200/JOP.2015.006148. Epub 2015 Sep 15. No abstract available.


Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.

Brodie SA, Li G, Harvey D, Khuri FR, Vertino PM, Brandes JC.

Oncotarget. 2015 Oct 13;6(31):30773-86. doi: 10.18632/oncotarget.5040.


Lung cancer in China: The new frontier?

Ramalingam SS, Khuri FR.

Cancer. 2015 Sep 1;121 Suppl 17:3058-60. doi: 10.1002/cncr.29569. No abstract available.


Early detection of lung cancer in China: The immediate imperative.

Veeraraghavan S, Ramalingam SS, Khuri FR.

Cancer. 2015 Sep 1;121 Suppl 17:3055-7. doi: 10.1002/cncr.29601. No abstract available.


Tobacco and China: The worst is yet to come.

Paskett ED, Bernardo BM, Khuri FR.

Cancer. 2015 Sep 1;121 Suppl 17:3052-4. doi: 10.1002/cncr.29600. No abstract available.

Supplemental Content

Loading ...
Support Center